Histomorphometry of the organic matrix of the femur in ovariectomized rats treated with sodium alendronate  by Haddad, Patricia Tanios et al.
r e v b r a s o r t o p . 2 0 1 5;5 0(1):100–104
www.rbo.org .br
Original article
Histomorphometry  of  the  organic  matrix  of the
femur in  ovariectomized  rats  treated  with  sodium
alendronate
Patricia Tanios Haddad, Márcio Salazar, Luzmarina Hernandes ∗
State University of Maringá (UEM), Maringá, Paraná, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 18 October 2013
Accepted 5 January 2014
Available online 31 December 2014
Keywords:
Ovariectomy
Alendronate
Osteoporosis
Bone matrix
a  b  s  t  r  a  c  t
Objective: To evaluate the effect of two different concentrations of sodium alendronate on
the  quantity of organic matrix in the femur of rats with estrogen suppression caused by
ovariectomy.
Methods: Sixty-days-old Wistar rats (Rattus norvegicus) were subjected to bilateral laparotomy
to  remove the ovaries. The animals were divided into a control group, in which they only
underwent laparotomy; an ovariectomized group (OVX); an ovariectomized group treated
with 1 mg/kg of alendronate (OVX 1 mg); and an ovariectomized group treated with 2 mg/kg
of  alendronate (OVX 2 mg). The rats received alendronate twice a week for 90 days. The
left  femur was then removed, ﬁxed and processed for embedding in parafﬁn. Semi-serial
sections stained with hematoxylin and eosin were used to determine the area occupied
by  organic bone matrix, by means of image analysis software. The animals’ weights were
obtained at the beginning and end of the experiment.
Results: The ovariectomized animals and those treated with 1 mg/kg of alendronate pre-
sented signiﬁcant increases in body weight (p < 0.05), in comparison with the control group.
Histomorphometric analysis revealed that in the animals treated with 2 mg/kg of alen-
dronate, the area (m2) occupied by organic matrix (1,81,900 ± 18,130) was similar (p > 0.05)
to  that of the non-ovariectomized control animals (2,04,800 ± 9590), which indicates that
this medication had a preventive effect with regard to bone mass loss.
Conclusion: The higher concentration of the medication, administered twice a week for 90
days, was more effective than the dose of 1 mg/kg over the same period.©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved. Work developed at the Animal Histotechnical Laboratory, State University of Maringá (UEM), Paraná, Brazil.
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Histomorfometria  da  matriz  orgânica  do  fêmur  de  ratas  ovariectomizadas
tratadas  com  alendronato  de  sódio
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Objetivo: Avaliar a efeito de duas concentrac¸ões diferentes de alendronato de sódio (ALN)
sobre  a quantidade de matriz orgânica no fêmur de ratas com supressão estrogênica provo-
cada por ovariectomia.
Métodos: Ratas Wistar (Rattus norvegicus) com 60 dias foram submetidas a laparotomia bilat-
eral  para remoc¸ão dos ovários. Os animais foram divididos em grupo controle, no qual
os  animais foram apenas laparotomizados; grupo ovariectomizado (OVX); grupo ovariec-
tomizado tratado com 1 mg/kg de ALN (OVX 1 mg); e grupo ovariectomizado tratado com 2
mg/kg de ALN (OVX 2 mg). Receberam ALN duas vezes por semana durante 90 dias. O fêmur
esquerdo foi coletado, ﬁxado e processado para inclusão em paraﬁna. Cortes semisseriados
corados com H&E foram usados para a obtenc¸ão, com um software de análise de imagens,
da área ocupada por matriz óssea orgânica. O peso dos animais foi obtido no inicio e no ﬁm
do  experimento.
Resultados: Os animais ovariectomizados e aqueles tratados com 1 mg/kg de ALN tiveram um
aumento signiﬁcativo (p < 0,05) no peso corporal quando comparados com o grupo controle.
A  análise histomorfométrica revelou que nos animais tratados com 2 mg/kg de ALN a área
(m2) ocupada por matriz orgânica (181.900 ± 18.130) foi semelhante (p > 0,05) àquela dos
animais controle não ovariectomizados (204.800 ± 9.590), o que indica um efeito preventivo
desse medicamento sobre a perda de massa óssea.
Conclusão: A maior concentrac¸ão do medicamento administrado duas vezes por semana
por  90 dias foi mais eﬁcaz do que a dose de 1 mg/kg no mesmo período.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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ostmenopausal osteoporosis is a disease characterized by
eterioration of the microarchitecture and reduction of bone
ass as a function of increased reabsorption by osteoclasts,
ith consequently greater susceptibility to fractures. This
ondition has very high prevalence and occurs more  fre-
uently than the sum of cases of myocardial infarct, breast
ancer and stroke.1 Osteoporosis should be considered to be
 public health problem,2 because it affects individuals with
egard to their social, physical and work functions and, there-
ore has a socioeconomic impact.3 The main cause of loss
f bone mass among women is the estrogen deﬁciency that
rises at the menopause.4
Over the last decade, bisphosphonates have become the
ornerstone of osteoporosis treatment.5 They are used for
reating and preventing this disease and oncological diseases
hat result in increased bone remodeling.6 Bisphosphonates
ave a chemical structure that has a strong afﬁnity with cal-
ium phosphate, which facilitates bonding to bone. During
one reabsorption,7 the drug is absorbed by the osteoclasts
nd causes rupture of the cytoskeleton, loss of the pleated
order, inhibition of lysosomal enzymes, loss of reabsorptive
ctivity and death due to apoptosis.8 Thus, there is a diminu-
ion of osteoclastic activity, without direct interference with
eoformation activity.9Sodium alendronate (ALN) is a second-generation amino-
isphosphonate that is a potent inhibitor of osteoclastic
eabsorption.10 Use of ALN suppresses bone remodeling11,12and increases bone mineral density (BMD), thereby contribut-
ing toward avoiding vertebral and non-vertebral fractures.
Through using ALN, bone turnover markers present lower
levels.12 Use of a speciﬁc ALN dose for treating osteoporosis
results in signiﬁcant deceleration of disease progression.8
The animal model most used for studying postmenopausal
osteoporosis comprises ovariectomy, because over a relatively
short period after ovariectomy, a state of osteopenia very simi-
lar to the human condition is obtained.13,14 By using animals, it
is also possible to investigate the different forms of treatment
and medications that exist on the market. However, there is
no consensus regarding the appropriate dose for tests on ani-
mals. The aim of this study was to evaluate the bone tissue
response in ovariectomized rats, to two different concentra-
tions of ALN, which is one of the most widely available drugs
on the market for osteoporosis treatment.
Materials  and  methods
All the procedures were approved by the Ethics Committee for
Animal Experimentation of the State University of Maringá
(protocol no. 033/2009).
Experimental  procedure
Female Wistar rats (Rattus norvegicus)  of 60 days of
age were anesthetized with an intramuscular injection
of 2-(2,6 xylidine)-5,6-dihydro-4H-1,3-thiazine hydrochloride
(Ronpun®) and ketamine hydrochloride (Ketalar®) in a 1:1
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Fig. 1 – Photomicrograph of the left femur of a female Wistar rat. (A) The marked areas indicate the microscope ﬁelds that
were captured by the Image-Pro Plus software for morphometric analysis on the area occupied by collagen. Original
magniﬁcation 4×. (B) This represents the way in which the measurement of the area occupied by collagen was obtained: the
s we
occupied by the organic matrix. All the calculations were per-
formed using the Excel software (Microsoft Corporation). The
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Fig. 2 – Difference between the initial and ﬁnal body weight
of the rats in the different groups: control; ovariectomized
(OVX); ovariectomized and treated with 1 mg/kg of sodiumtotal area was determined and the areas of the empty space
Original magniﬁcation 20×.  Hematoxylin and eosin.
ratio. This association was used at a rate of 1 mL/kg of body
weight for laparotomy and ovary removal. The procedures
were started only after the interdigital and ocular reﬂexes
had disappeared. Pulmonary ventilation was maintained in a
spontaneous manner. Until recovery from the anesthesia, the
animals were observed with regard to their ocular reﬂex (by
stimulating the upper eyelid using gauze), respiration rate (by
direct observation of the thoracic-abdominal movements) and
heart rate (checked using a pediatric stethoscope attached to
the anterior region of the thorax).
The animals were divided into four groups of eight ani-
mals each: a control group, in which the animals only
underwent laparotomy; an ovariectomized group (OVX); an
ovariectomized group that was treated with 1 mg/kg of ALN
(OVX 1 mg); and an ovariectomized group that was treated
with 2 mg/kg of ALN (OVX 2 mg). After recovery from the anes-
thesia, the animals were kept in groups of four animals per
cage, at a temperature of 20 ◦C, with dark/light cycles of 12 h
and free access to water and food throughout the period of
the experiment. All the animals were weighed at the start and
end of the experiment.
During the week following the ovariectomy and for the
subsequent 90 days, the treated groups were injected intra-
muscularly with ALN 1 mg/kg or 2 mg/kg, twice a week, always
at the same time of day. After the treatment period, the ani-
mals were sacriﬁced by means of an overdose of ketamine. The
left femur of each animal was removed and ﬁxed in a solution
of 4% paraformaldehyde for 48 h. The soft tissues were then
dissected and, following this, the bone was demineralized in
formic acid for 21 days. The samples were then washed in
running water for 6 h and processed for embedding in paraf-
ﬁn. Semi-serial sections of thickness 7 m were cut along the
major axis of the femur. These sections were stained with
hematoxylin and eosin (H&E) for analysis.
To determine the area occupied by the organic matrix, two
images of a standardized area in the proximal diaphysis were
captured, just below the epiphyseal disk of the left femur
(Fig. 1A and B). The images were obtained from three sections
per slide, on four slides per animal, thus totaling 24 images
per animal. The image  capture system used consisted of an
Olympus BX41 microscope (Tokyo, Japan) with an Olympus Qre  summed and then subtracted from the total area.
Color 3 RT camera (Tokyo, Japan) coupled to it. The images
were obtained using a 20× objective lens.
The area occupied by collagen was assessed using image
analysis software (Image-Pro Plus®, version 4.5, Media Cyber-
netics, Silver Spring, MD, USA), which obtained the area in
square micrometers.
The area evaluated was composed of trabecular bone and
to calculate the area occupied by the organic matrix, the fol-
lowing methodology was adopted: ﬁrstly, the total area of the
image  seen using the 20× objective lens was calculated; then,
the empty areas on each slide (corresponding to trabeculated
bone areas occupied by bone marrow) were measured and
summed in order to subsequently subtract these areas from
the total area (Fig. 2). The ﬁnal result corresponded to the areaalendronate (OVX 1 mg); and ovariectomized and treated
with 2 mg/kg of sodium alendronate (OVX 2 mg). Results are
expressed as mean ± standard deviation. P < 0.05,
comparing * with **.
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Fig. 3 – Area (m2) occupied by organic bone matrix in the
different groups: control; ovariectomized (OVX);
ovariectomized and treated with 1 mg/kg of sodium
alendronate (OVX 1 mg); and ovariectomized and treated
with 2 mg/kg of sodium alendronate (OVX 2 mg). Results are
expressed as mean ± standard deviation. P < 0.05,
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Conclusionomparing * with **.
ean area in m2 in each animal was obtained for statistical
omparisons.
tatistical  analysis
he statistical analysis was performed using the GraphPad
rism R 3.1 software. The data obtained were presented as the
ean ± standard deviation. The variance analysis test used
as ANOVA. Tukey’s test was used as a post-test for com-
arisons between the means. The signiﬁcance level used was
%.
esults
he animals’ initial and ﬁnal weights in grams are shown in
ig. 2. Fig. 3 presents the results from the analysis on the area
m2) occupied by the organic bone matrix.
iscussion
xperimental ovariectomy is a study model that makes it pos-
ible to evaluate the consequences, in animals, of loss of bone
ass in a variety of situations.15 The commonest study topic is
he efﬁcacy of medications available on the market for treating
steoporosis.4,8,10,16 In this model, a period of three months
fter removal of the ovaries is sufﬁcient for a signiﬁcant loss
f bone mass in the femurs of ovariectomized rats to have
ccurred.17
Ovariectomy leads to a signiﬁcant progressive increase in
ody weight.18 In the present study, the ovariectomized rats
ere treated with two different concentrations of ALN for 90
ays. There was an increase in body weight in the untreated
variectomized rats and in those that received ALN at the rate
f 1 mg/kg. The animals that received 2 mg/kg did not present
ny change in body weight, in comparison with the control;5 0(1):100–104 103
group. These results demonstrate that the dose of 2 mg/kg was
more  efﬁcient in preventing gains in body mass.
Estrogen deﬁciency may be related to decreased num-
bers of leptin receptors in the hypothalamus, thereby causing
diminished satiety,19 greater food intake and consequent
weight gain. On the other hand, there is also the possibility
of diminished energy expenditure in females with estrogen
deﬁciency, which would facilitate the gain in body mass.20
The ovariectomized rats received treatment with 1 or
2 mg/kg of ALN twice a week. It is important to emphasize
that the treatment started one day after ovariectomy and,
therefore, these female rats did not already present a con-
dition of bone loss. Through histomorphometric analysis on
the organic matrix, it was observed that the treatment with
2 mg/kg of ALN had a preventive effect on the loss of bone
mass. The animals that received 1 mg/kg presented a reduc-
tion in bone matrix similar to that of the ovariectomized
animals.
Bisphosphonates decrease the degree of bone growth
but without interfering with the quality of the mechanical
resistance of the bone.21 In other words, ALN enables pre-
vention of reabsorption, but the bone maintains its normal
structural and mechanical characteristics.22 Bisphosphonates
make the bone turnover slower and provide more  time for
bone structural organization, without impairing or altering the
mechanical properties of the tissue.23
In humans, the recommended dose of ALN is 1 mg/kg of
body weight, once a week. However, rats have a metabolism
that is twice as fast as that of humans and for this reason, the
drug was administered twice a week. The dose of 1 mg/kg was
chosen to be similar to that applied to humans. On the other
hand, the dose of 2 mg/kg was chosen to be the test dose.
There is no consensus between different authors regarding
the ALN dose that should be administered to animals. Ito
et al.16 observed, in a study on ovariectomized rats, that daily
administration of 0.2 mg  and 1 mg/kg, for 12 weeks, caused a
signiﬁcant increase in the quantity of organic matrix, in rela-
tion to the untreated ovariectomized rats; the bone mineral
density (BMD) of the ovariectomized group was 24.2% lower
than that of the control group. Allen24 evaluated the concen-
trations of 0.1, 0.2 and 1 mg/kg/day of ALN during a one-year
treatment period. It was observed that the best results were
obtained with higher concentrations of the medication.
Several other authors have tested different concentrations
of ALN, at different times, either in or not in association with
other substances such as vitamin K,25 vitamin D3,16 calcium26
and estradiol.4 The results from these studies demonstrated
in a general manner that ALN has an anabolic effect on loss
of bone mass in ovariectomized animals.
Our results showed that the dose of 1 mg/kg twice a week
was insufﬁcient to stimulate an anabolic effect. However,
Masaya et al.16 and Allen24 demonstrated that this same con-
centration, given as daily treatment, produced an increase in
bone mineral density after 12 weeks and one year, respectively.At least three parameters need to be taken into consider-
ation when ALN is used in animal models: the dose, treatment
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duration and posology. Thus, for lower concentrations of the
medication, the doses should be more  frequent and the treat-
ment should be for a longer period, in order to achieve the
desired results; whereas for higher concentrations, the fre-
quency of administration can be lower.
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